Michael C Milone

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi Laboratory testing for prescription opioids
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Med Toxicol 8:408-16. 2012
  2. ncbi Adoptive immunotherapy: new ways to skin the cat?
    Michael C Milone
    Abramson Family Cancer Research Institute and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, PA 19104, USA
    Clin Immunol 117:101-3. 2005
  3. ncbi Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104 5160, USA
    Mol Ther 17:1453-64. 2009
  4. ncbi Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    Carmine Carpenito
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 106:3360-5. 2009
  5. ncbi Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS
    Qian Zhang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 118:3062-71. 2011
  6. ncbi In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes
    Natalie A Christian
    Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, 210 S 33rd Street Room 240 Skirkanich Hall, Philadelphia, PA 19104, USA
    Mol Imaging Biol 11:167-77. 2009
  7. ncbi Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules
    Megan M Suhoski
    Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104 5160, USA
    Mol Ther 15:981-8. 2007
  8. ncbi Therapeutic drug monitoring of mycophenolic acid
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Clin J Am Soc Nephrol 2:1062-72. 2007
  9. ncbi Substrate rigidity regulates human T cell activation and proliferation
    Roddy S O'Connor
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 189:1330-9. 2012
  10. ncbi F-actin polymerization and retrograde flow drive sustained PLCĪ³1 signaling during T cell activation
    Alexander Babich
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Cell Biol 197:775-87. 2012

Collaborators

Detail Information

Publications14

  1. ncbi Laboratory testing for prescription opioids
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
    J Med Toxicol 8:408-16. 2012
    ..Improved testing algorithms and more research into the effective use of drug testing in the clinical setting, particularly in pain medicine and substance abuse, are needed...
  2. ncbi Adoptive immunotherapy: new ways to skin the cat?
    Michael C Milone
    Abramson Family Cancer Research Institute and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, PA 19104, USA
    Clin Immunol 117:101-3. 2005
  3. ncbi Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104 5160, USA
    Mol Ther 17:1453-64. 2009
    ..Together these results suggest that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematologic malignancies and hence maximize their antitumor activity...
  4. ncbi Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    Carmine Carpenito
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 106:3360-5. 2009
    ..Genetically redirected T cells have promise of targeting T lymphocytes to tumor antigens, confer resistance to the tumor microenvironment, and providing immunosurveillance...
  5. ncbi Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS
    Qian Zhang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Blood 118:3062-71. 2011
    ..These data also show that the DNA methylation status of the intronic CpG island affects transcriptional activity of the ICOS gene and, consequently, modulates the concentration of the expressed ICOS protein...
  6. ncbi In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes
    Natalie A Christian
    Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, 210 S 33rd Street Room 240 Skirkanich Hall, Philadelphia, PA 19104, USA
    Mol Imaging Biol 11:167-77. 2009
    ..Fluorescence is commonly used for in vitro and postmortem biomedical studies but has been limited by autofluorescence at the whole-animal level...
  7. ncbi Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules
    Megan M Suhoski
    Department of Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104 5160, USA
    Mol Ther 15:981-8. 2007
    ..Finally, the aAPCs provide an efficient platform to expand genetically modified T cells and to maintain CD28 expression on CD8 T cells. Therefore, K562-based aAPCs have therapeutic potential for adoptive immunotherapies and vaccinations...
  8. ncbi Therapeutic drug monitoring of mycophenolic acid
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Clin J Am Soc Nephrol 2:1062-72. 2007
  9. ncbi Substrate rigidity regulates human T cell activation and proliferation
    Roddy S O'Connor
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Immunol 189:1330-9. 2012
    ..Substrate rigidity should therefore be a consideration in the development of T cell culture systems as well as when interpreting results of T cell activation based upon solid-phase immobilization of TCR/CD3 and CD28 ligands...
  10. ncbi F-actin polymerization and retrograde flow drive sustained PLCĪ³1 signaling during T cell activation
    Alexander Babich
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Cell Biol 197:775-87. 2012
    ..These studies highlight the importance of ongoing actin polymerization as a central driver of actomyosin retrograde flow, MC centralization, and sustained Ca(2+) signaling...
  11. ncbi Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis
    Qian Zhang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 106:15843-8. 2009
    ..These findings provide additional rationale for the therapeutic inhibition of DNA methyltransferases in ALK+ TCL. They also suggest that treatment with TNFalpha may be highly effective in this type of lymphoma...
  12. ncbi Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation
    Naoki Kunii
    Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 5156, USA
    Hum Gene Ther 24:27-37. 2013
    ..These results indicate that interruption of LAT ubiquitylation is a promising strategy to augment effector T cell function for adoptive cell therapy...
  13. ncbi Investigative and clinical applications of synthetic immune synapses
    Michael C Milone
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    Wiley Interdiscip Rev Nanomed Nanobiotechnol 5:75-85. 2013
    ..Bioreactors based on these concepts may find immediate application in enhancing cellular-based immunotherapy...
  14. ncbi Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling
    Natalie A Christian
    School of Engineering and Applied Science, Department of Bioengineering, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Bioconjug Chem 18:31-40. 2007
    ..7 +/- 0.1 fmol of NIR fluorophore. Our studies will enable future in vivo tracking of ex vivo labeled DCs by NIR fluorescence based imaging...